Citius Pharmaceuticals to Present at the LD Micro Invitational XIV Investor Conference

Rhea-AI Summary

Citius Pharmaceuticals, Inc. announced that Chairman and CEO Leonard Mazur will present at the 14th Annual LD Micro Invitational investor conference in New York City on April 9, 2024. The presentation will be both in-person and virtual, starting at 3:30pm ET.

CRANFORD, N.J., April 4, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced that Chairman and CEO Leonard Mazur will present at the 14th Annual LD Micro Invitational investor conference being held April 8-9, 2024, in New York City.

Conference Details:

Presentation:	3:30pm ET on April 9, 2024
Format:	In-person and virtual
Location:	Sofitel New York, New York City
Conference attendance:	Register on the conference website
Livestream:	Register here
1x1 meetings:	Upon request by registered investors

About Citius Pharmaceuticals, Inc.

Citius Pharma is a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products. The Company's diversified pipeline includes two late-stage product candidates. At the end of 2023, Citius completed enrollment in a Phase 3 Pivotal superiority trial of Mino-Lok®, an antibiotic lock solution to salvage catheters in patients with catheter-related bloodstream infections. A Biologics License Application for LYMPHIR™, a novel IL-2R immunotherapy for an initial indication in the treatment of cutaneous T-cell lymphoma, is currently under review by the FDA with August 13, 2024 assigned as the PDUFA target action date. Citius previously announced plans to form Citius Oncology, a standalone publicly traded company with LYMPHIR as its primary asset. LYMPHIR received orphan drug designation by the FDA for the treatment of CTCL and PTCL. In addition, Citius completed enrollment in its Phase 2b trial of CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids. For more information, please visit www.citiuspharma.com.

Investor Contact:

Ilanit Allen
ir@citiuspharma.com
908-967-6677 x113

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/citius-pharmaceuticals-to-present-at-the-ld-micro-invitational-xiv-investor-conference-302108125.html

SOURCE Citius Pharmaceuticals, Inc.

FAQ

When will Chairman and CEO Leonard Mazur present at the 14th Annual LD Micro Invitational investor conference?

Chairman and CEO Leonard Mazur will present at the 14th Annual LD Micro Invitational investor conference on April 9, 2024.

Where will the conference take place?

The conference will be held at Sofitel New York, New York City.

What time will the presentation start on April 9, 2024?

The presentation will start at 3:30pm ET on April 9, 2024.

How can investors attend the conference?

Investors can register on the conference website to attend the event.

Will there be a livestream available for the conference?

Yes, there will be a livestream available for the conference. Investors can register for the livestream on the provided link.

Are 1x1 meetings available for investors?

Yes, 1x1 meetings are available upon request by registered investors.